000296172 001__ 296172
000296172 005__ 20250113121215.0
000296172 0247_ $$2doi$$a10.1002/cam4.70404
000296172 0247_ $$2pmid$$apmid:39781572
000296172 0247_ $$2pmc$$apmc:PMC11712150
000296172 037__ $$aDKFZ-2025-00099
000296172 041__ $$aEnglish
000296172 082__ $$a610
000296172 1001_ $$0P:(DE-He78)2c984a7f2206879886962a4375764178$$aBlickle, Patricia$$b0$$eFirst author$$udkfz
000296172 245__ $$aPretreatment Fatigue in Breast Cancer Patients: Comparison With Healthy Controls and Associations With Biopsychosocial Variables.
000296172 260__ $$aHoboken, NJ$$bWiley$$c2025
000296172 3367_ $$2DRIVER$$aarticle
000296172 3367_ $$2DataCite$$aOutput Types/Journal article
000296172 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736751485_10409
000296172 3367_ $$2BibTeX$$aARTICLE
000296172 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296172 3367_ $$00$$2EndNote$$aJournal Article
000296172 500__ $$a#EA:C110#LA:C110#
000296172 520__ $$aCancer-related fatigue is one of the most common burdens of cancer patients. To date, most studies focused on fatigue during or after treatment. However, investigation of pretreatment fatigue is crucial to identify causal or risk factors other than cancer therapy and to enable timely fatigue management.Two hundred and thirty-two breast cancer patients (mean age = 55.6) and 41 healthy participants (mean age = 49.3) were recruited via the National Center for Tumor Diseases (NCT) Heidelberg. Patient-reported outcomes were assessed with the EORTC QLQ-FA12 for fatigue, the EORTC QLQ-C30 for functioning, the STAI for anxiety, the CESD-R for depression and the PSQI for sleep disturbance. Descriptive analyses and logistic regression models were performed using baseline data before start of cancer treatment. The thresholds of clinical importance (TCI) were applied to test for clinically relevant fatigue.Compared to the healthy participants, patients scored significantly higher in physical, emotional, and total fatigue, in depression, in global health status and in all functioning scales except cognitive function (all p < 0.01). 48.7% of all patients reported clinically relevant fatigue. Being younger, being obese, having low education, or low social support was associated with a higher likelihood of clinically relevant fatigue before treatment. Higher depression and anxiety scores, poorer sleep quality and global health status, and impaired functioning seemed to get along with an increased likelihood of scoring above the TCI of fatigue (all p < 0.001).Our study results suggest that fatigue screening, patient-centered fatigue education and psychosocial support may be needed already from the time of cancer diagnosis.
000296172 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296172 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296172 650_7 $$2Other$$abreast cancer patients
000296172 650_7 $$2Other$$acancer
000296172 650_7 $$2Other$$acancer‐related fatigue
000296172 650_7 $$2Other$$aoncology
000296172 650_7 $$2Other$$apatient‐reported outcomes
000296172 650_7 $$2Other$$apretreatment fatigue
000296172 650_7 $$2Other$$apsychological factors
000296172 650_7 $$2Other$$apsycho‐oncology
000296172 650_7 $$2Other$$aquality of life
000296172 650_7 $$2Other$$asupportive care
000296172 650_2 $$2MeSH$$aHumans
000296172 650_2 $$2MeSH$$aFemale
000296172 650_2 $$2MeSH$$aFatigue: etiology
000296172 650_2 $$2MeSH$$aFatigue: psychology
000296172 650_2 $$2MeSH$$aBreast Neoplasms: psychology
000296172 650_2 $$2MeSH$$aBreast Neoplasms: complications
000296172 650_2 $$2MeSH$$aMiddle Aged
000296172 650_2 $$2MeSH$$aCase-Control Studies
000296172 650_2 $$2MeSH$$aAdult
000296172 650_2 $$2MeSH$$aAged
000296172 650_2 $$2MeSH$$aQuality of Life
000296172 650_2 $$2MeSH$$aDepression: etiology
000296172 650_2 $$2MeSH$$aDepression: psychology
000296172 650_2 $$2MeSH$$aAnxiety: psychology
000296172 650_2 $$2MeSH$$aAnxiety: etiology
000296172 650_2 $$2MeSH$$aRisk Factors
000296172 650_2 $$2MeSH$$aPatient Reported Outcome Measures
000296172 650_2 $$2MeSH$$aSurveys and Questionnaires
000296172 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b1$$udkfz
000296172 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b2$$eLast author$$udkfz
000296172 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.70404$$gVol. 14, no. 1, p. e70404$$n1$$pe70404$$tCancer medicine$$v14$$x2045-7634$$y2025
000296172 909CO $$ooai:inrepo02.dkfz.de:296172$$pVDB
000296172 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2c984a7f2206879886962a4375764178$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000296172 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000296172 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000296172 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296172 9141_ $$y2025
000296172 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:13Z
000296172 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:13Z
000296172 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2021-04-16T15:13:13Z
000296172 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-04-16T15:13:13Z
000296172 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000296172 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000296172 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000296172 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000296172 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000296172 980__ $$ajournal
000296172 980__ $$aVDB
000296172 980__ $$aI:(DE-He78)C110-20160331
000296172 980__ $$aUNRESTRICTED